06:40 AM EDT, 10/15/2026 (MT Newswires) -- Arecor Therapeutics (AREC.L) secured new patents in Europe, the US and India for its concentrated and rapid-acting insulin, AT278. The clinical-stage biotechnology company said Thursday that the European Patent Office and the US Patent and Trademark Office issued separate patents for the use of the proprietary product in automated insulin delivery systems, while the Indian Patent Office issued a fresh protection for the novel composition of AT278.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.